SE9701162D0 - New use II - Google Patents

New use II

Info

Publication number
SE9701162D0
SE9701162D0 SE9701162A SE9701162A SE9701162D0 SE 9701162 D0 SE9701162 D0 SE 9701162D0 SE 9701162 A SE9701162 A SE 9701162A SE 9701162 A SE9701162 A SE 9701162A SE 9701162 D0 SE9701162 D0 SE 9701162D0
Authority
SE
Sweden
Prior art keywords
new use
oxytocin
wounds
estrogen
curative
Prior art date
Application number
SE9701162A
Other languages
English (en)
Swedish (sv)
Inventor
Thomas Lundeberg
Moberg Kerstin Uvnaes
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE9701162A priority Critical patent/SE9701162D0/xx
Publication of SE9701162D0 publication Critical patent/SE9701162D0/xx
Priority to EP98912862A priority patent/EP1003542B1/en
Priority to US09/381,799 priority patent/US6262021B1/en
Priority to DE69811371T priority patent/DE69811371T2/de
Priority to ES98912862T priority patent/ES2194308T3/es
Priority to PCT/SE1998/000554 priority patent/WO1998043661A1/en
Priority to AU67550/98A priority patent/AU749479B2/en
Priority to JP54154798A priority patent/JP2001519786A/ja
Priority to AT98912862T priority patent/ATE232393T1/de
Priority to CN98803766A priority patent/CN1251530A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9701162A 1997-03-27 1997-03-27 New use II SE9701162D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9701162A SE9701162D0 (sv) 1997-03-27 1997-03-27 New use II
EP98912862A EP1003542B1 (en) 1997-03-27 1998-03-26 Use of substances having oxytocin activity for preparation of medicaments for wound healing
US09/381,799 US6262021B1 (en) 1997-03-27 1998-03-26 Use of substances having oxytocin activity for preparation of medicaments for wound healing
DE69811371T DE69811371T2 (de) 1997-03-27 1998-03-26 Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung
ES98912862T ES2194308T3 (es) 1997-03-27 1998-03-26 Utilizacion de sustancias con una actividad de oxitocina en la preparacion de medicamentos para la curacion de heridas.
PCT/SE1998/000554 WO1998043661A1 (en) 1997-03-27 1998-03-26 Use of substances having oxytocin activity for preparation of medicaments for wound healing
AU67550/98A AU749479B2 (en) 1997-03-27 1998-03-26 Use of substances having oxytocin activity for preparation of medicaments for wound healing
JP54154798A JP2001519786A (ja) 1997-03-27 1998-03-26 創傷治癒用医薬の製造のためのオキシトシン活性を有する物質の使用
AT98912862T ATE232393T1 (de) 1997-03-27 1998-03-26 Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung
CN98803766A CN1251530A (zh) 1997-03-27 1998-03-26 具有催产素活性的物质在制备用于创伤愈合的药剂方面的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701162A SE9701162D0 (sv) 1997-03-27 1997-03-27 New use II

Publications (1)

Publication Number Publication Date
SE9701162D0 true SE9701162D0 (sv) 1997-03-27

Family

ID=20406369

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9701162A SE9701162D0 (sv) 1997-03-27 1997-03-27 New use II

Country Status (10)

Country Link
US (1) US6262021B1 (xx)
EP (1) EP1003542B1 (xx)
JP (1) JP2001519786A (xx)
CN (1) CN1251530A (xx)
AT (1) ATE232393T1 (xx)
AU (1) AU749479B2 (xx)
DE (1) DE69811371T2 (xx)
ES (1) ES2194308T3 (xx)
SE (1) SE9701162D0 (xx)
WO (1) WO1998043661A1 (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004224A1 (en) * 1994-05-04 2008-01-03 Hlavka Joseph J Dermatological uses of tri-, tetra-, penta-, and polypeptides
SE9701184D0 (sv) * 1997-04-01 1997-04-01 Karolinska Innovations Ab Substanser för att åstadkomma preferens och skapa acceptans
SE9803272D0 (sv) * 1998-09-25 1998-09-25 Kerstin Uvnaes Moberg A drug for cell regeneration
SE0001440D0 (sv) * 2000-04-18 2000-04-18 Entretech Medical Ab A drug against climacteric disorders
SE0100684D0 (sv) * 2001-02-28 2001-02-28 Kerstin Uvnaes Moberg New subject-matter
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
ES2315455T3 (es) * 2003-03-27 2009-04-01 Pantarhei Bioscience B.V. Uso de estrogenos para el tratamiento de infertilidad en maniferos machos.
JO2937B1 (en) 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
JP4747364B2 (ja) * 2005-04-04 2011-08-17 独立行政法人産業技術総合研究所 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
US7660413B2 (en) * 2005-04-08 2010-02-09 Shahram Partovi Secure digital couriering system and method
JP2009506076A (ja) 2005-08-26 2009-02-12 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 三叉神経疼痛のための薬物送達のための治療手順
CA2641959C (en) * 2006-02-10 2016-12-20 Ferring B.V. Novel compounds
US20080004223A1 (en) * 2006-05-17 2008-01-03 Hlavka Joseph J Dermatological uses of the tripeptide melanocyte stimulating inhibitory factor (mif)
WO2009037586A2 (en) * 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
WO2009033820A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
RU2010114024A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение гонадорелина в качестве терапевтического средства
JP2010538989A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Ｈｂｖ感染等の治療における治療剤としてのｎｆ−カッパーｂインヒビターｓｎ５０の使用、及び必要に応じたアンギオテンシンｉｉｉの使用
ATE522225T1 (de) * 2007-09-11 2011-09-15 Mondobiotech Lab Ag Verwendung des peptids phpfhlfvy (renin- inhibitor) in anti-angiogenischer therapie von gewissen erkrankungen
WO2009046826A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a cyclic penta-peptide as a therapeutic agent
ES2567706T3 (es) * 2007-10-29 2016-04-26 Helix Biomedix Inc. Tetrapéptidos protectores para cuidado cutáneo
AU2011252764B2 (en) * 2010-05-14 2012-12-13 Charlotte L. Keating Neuropsychopharmacological treatment regimes for treating psychological disorders
AU2011268139B2 (en) * 2010-06-18 2014-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hair follicle neogenesis
US9585935B2 (en) * 2010-07-30 2017-03-07 The Regents Of The University Of California Intranasal oxytocin treatment to improve schizophrenia
SE536091C2 (sv) 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
DE102011118016A1 (de) * 2011-10-26 2013-05-02 Henkel Ag & Co. Kgaa Kosmetische Mittel enthaltend Oxytocin und Riechstoffe
US9387183B2 (en) 2011-12-28 2016-07-12 Kuwait University Method of treating diabetes-related impaired wound healing
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US10478526B2 (en) 2013-05-03 2019-11-19 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Skin substitutes and methods for hair follicle neogenesis
PE20161559A1 (es) * 2014-06-03 2017-01-12 Hoffmann La Roche Peptidos como agonistas de la oxitocina
EP4331670A3 (en) 2015-01-07 2024-05-29 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
CN107456570A (zh) * 2017-07-31 2017-12-12 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 催产素在促进缺血超长随意皮瓣存活中的作用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274060A (en) * 1962-05-23 1966-09-20 Armour Pharma Treatment of multiple sclerosis with oxytocin
NL129421C (xx) * 1963-08-30 1900-01-01
EP0300036A4 (en) * 1987-01-30 1989-06-14 Biomed Res Consultants Ltd PHARMACEUTICAL COMPOSITIONS BASED ON VASOPRESSIN.
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
SE9701161D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I

Also Published As

Publication number Publication date
CN1251530A (zh) 2000-04-26
AU749479B2 (en) 2002-06-27
DE69811371T2 (de) 2003-12-18
AU6755098A (en) 1998-10-22
JP2001519786A (ja) 2001-10-23
WO1998043661A1 (en) 1998-10-08
US6262021B1 (en) 2001-07-17
ATE232393T1 (de) 2003-02-15
ES2194308T3 (es) 2003-11-16
EP1003542B1 (en) 2003-02-12
DE69811371D1 (de) 2003-03-20
EP1003542A1 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
SE9701162D0 (sv) New use II
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
BR9906477A (pt) Cicatrizante de feridas enriquecido com plaquetas aperfeiçoado
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
WO2002078755A3 (en) Medical dressing comprising an antimicrobial silver compound
SE9701161D0 (sv) New use I
ATE243196T1 (de) Piperidine und pyrrolidine
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
ES2181165T3 (es) Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
DE69034070T2 (de) Racemisches Huperzin A
ES2080037T1 (es) Medicamento de uso topico con actividad cicatrizante.
ID24870A (id) Penggunaan senyawa vanadium, garam dan kompleksnya yang dapat diterima secara fisiologi
ATE275966T1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
DE60221884D1 (de) Mediziniscer verband
DE68910973D1 (de) Arzneimittelzusammensetzung, enthaltend deoxyribonukleoside für heilung von wunden.
FR2794976B1 (fr) Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
GB2368523A (en) Solid wound healing formulations containing fibronectin
SE8802040D0 (sv) New use
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
BR9711960A (pt) Verapamil como um medicamento para o tratamento de angina
ATE314851T1 (de) Synergistische wechselwirkung von abacavir und alovudin